Bronchiectasis is a chronic airway disease characterized by permanent, abnormal dilation of the bronchi due to destruction of the elastic and muscular components of the bronchial walls, leading to impaired mucociliary clearance and recurrent infections.

Bronchiectasis

Bronchiectasis is the pathological, permanent, irreversible dilatation of the bronchi (proximal medium-sized airways > 2 mm in diameter) ^[1]^[2]. The name itself tells you the condition: "bronchi" = the airways, "ectasis" (Greek ektasis) = stretching or dilatation. So it literally means "stretched-out bronchi."

This is not just a radiological finding — it is a clinical syndrome characterised by a vicious cycle of transmural inflammation → impaired mucociliary clearance → mucus stasis → chronic bacterial colonisation → further inflammation and structural destruction of the bronchial wall. Once the bronchial wall is destroyed, the damage is permanent — hence "irreversible."

Key conceptual distinction: Bronchiectasis is a final common pathway of many diseases, not a single disease in itself. Always think: "What caused the bronchiectasis?" — i.e., it is secondary to an underlying aetiology.

GC High Yield

"Cause: mostly idiopathic (needs to exclude other causes, e.g. post-infection and TB)" — GC lecture slide ^[1]. Up to 50% of cases are idiopathic even after full workup, but you must actively exclude treatable aetiologies.

2. Epidemiology and Risk Factors

Global prevalence is rising, partly due to better detection with HRCT and ageing populations.
Prevalence estimates range from ~50–560 per 100,000 adults depending on the population studied.
Female predominance in many cohorts (though post-infectious bronchiectasis in some Asian series shows equal or slight male predominance).
Age: Prevalence increases with age (peak in the elderly, > 60–70 years), though it can present in childhood (e.g., cystic fibrosis, primary ciliary dyskinesia, primary immunodeficiency).

Post-infectious causes are the most important acquired aetiology in Hong Kong, particularly:
- Tuberculosis (TB) — the single most common identifiable cause in HK; post-TB bronchiectasis is extremely prevalent given the historically high TB burden ^[1]^[2].
- Childhood infections: pertussis, measles, adenovirus pneumonia (historically more common before vaccination).
Non-tuberculous mycobacteria (NTM), particularly Mycobacterium avium complex (MAC), are an increasingly recognised association — NTM can be both a cause and a consequence of bronchiectasis.
Cystic fibrosis is rare in ethnic Chinese populations (incidence ~1/100,000 vs. 1/2,500 in Caucasians) ^[3] — so CF is far less likely as an aetiology in HK compared to Western countries.

Risk Factor	Mechanism
Previous severe lower respiratory tract infection (TB, pneumonia, pertussis, measles)	Direct destruction of bronchial wall elastin and cartilage during intense inflammation
Immunodeficiency (primary or secondary)	Impaired pathogen clearance → recurrent/chronic infections → airway damage
Chronic obstructive pulmonary disease (COPD)	Chronic airway inflammation + mucus hypersecretion; there is significant overlap ("COPD-bronchiectasis overlap")
Autoimmune/connective tissue disease (RA, Sjögren's)	Lymphocytic infiltration and fibrosis of bronchial wall
Allergic bronchopulmonary aspergillosis (ABPA)	Hypersensitivity reaction to Aspergillus → eosinophilic inflammation → central bronchiectasis
Gastro-oesophageal reflux / chronic aspiration	Repeated chemical/infectious insult to lower airways

3. Anatomy and Function of Affected Structures

To understand why bronchiectasis is such a problem, you need to appreciate normal bronchial architecture:

Bronchial wall layers (from inside out):
- Mucosa: Pseudostratified ciliated columnar epithelium with goblet cells → produces the mucociliary escalator (mucus traps particles; cilia beat in coordinated waves to move mucus up towards the pharynx for swallowing or expectoration).
- Submucosa: Contains bronchial glands (serous and mucous), blood vessels (bronchial arteries from the aorta), nerves, and elastic tissue.
- Cartilage and smooth muscle: Cartilage plates provide structural rigidity and prevent collapse; smooth muscle controls airway calibre.
- Adventitia: Connective tissue continuous with the lung parenchyma.
Bronchial arterial supply:
- Bronchial arteries arise from the thoracic aorta (systemic pressure).
- In bronchiectasis, these arteries undergo hypertrophy and neovascularisation (tortuous, dilated vessels) in response to chronic inflammation.
- This is why haemoptysis in bronchiectasis can be massive — you are bleeding from hypertrophied systemic-pressure vessels, not low-pressure pulmonary arteries.
Mucociliary clearance:
- The key defence mechanism of the conducting airways.
- Requires: (a) normal ciliary structure and beat frequency, (b) appropriate quantity and rheology (viscosity) of airway surface liquid, (c) intact epithelium.
- Any process that disrupts mucociliary clearance predisposes to bronchiectasis.

Destruction of elastic tissue and cartilage → the wall loses its structural scaffolding → the airway dilates and cannot recoil.
Loss of ciliated epithelium → replaced by squamous metaplasia or granulation tissue → cilia are destroyed → mucociliary escalator fails.
Bronchial gland hypertrophy → mucus hypersecretion → copious sputum.
Bronchial artery hypertrophy → risk of haemoptysis.
Peribronchial fibrosis → further distortion and tethering of the airway.

4. Aetiology (with Hong Kong Focus)

GC High Yield

"Cause: mostly idiopathic (needs to exclude other causes, e.g. post-infection and TB)" ^[1]. In clinical practice and exams, always consider and systematically exclude secondary causes.

Infection	Notes
Tuberculosis	Most common identifiable cause in Hong Kong ^[1]^[2]. Post-TB bronchiectasis is typically upper-lobe predominant (reflecting the predilection of reactivation TB for upper lobes). Mechanism: caseous necrosis destroys bronchial wall → fibrosis → traction and dilatation.
Childhood pneumonia (bacterial)	Severe necrotising pneumonia in childhood (e.g., S. aureus, Klebsiella) can destroy bronchial architecture before full maturation.
Pertussis (whooping cough) / Measles	Historically important pre-vaccination causes. Intense airway inflammation and mucus plugging in childhood → bronchial damage.
Adenovirus	Particularly types 3, 7, 21 in children → Swyer-James/MacLeod syndrome (unilateral hyperlucent lung with bronchiectasis).
Allergic bronchopulmonary aspergillosis (ABPA)	Hypersensitivity to Aspergillus fumigatus → mucoid impaction, eosinophilic inflammation → characteristically central bronchiectasis (affecting proximal bronchi, unlike most other causes which tend to affect more peripheral airways) ^[2].

Condition	Key Details
Cystic fibrosis (CF)	AR mutation in CFTR gene (chromosome 7) → defective Cl⁻ channel → thick, dehydrated airway secretions → impaired mucociliary clearance → chronic infection (S. aureus early, then P. aeruginosa, Burkholderia cepacia complex) → bronchiectasis. Classical triad: ↑sweat Cl⁻ + recurrent lung infections + pancreatic insufficiency ^[3]. Rare in Chinese/HK population. Most common cause of bronchiectasis in Caucasian children/young adults.
Primary ciliary dyskinesia (PCD)	AR inheritance; mutation in dynein arm proteins (or other ciliary structural proteins) → dysmotile or immotile cilia → impaired mucociliary clearance → bronchiectasis + chronic sinusitis + otitis media + male infertility (immotile sperm).
Kartagener's syndrome	PCD + situs inversus (mirror-image reversal of thoracic and abdominal organs) ^[2]. Situs inversus occurs because cilia are also needed for left-right axis determination during embryogenesis (nodal cilia). Only ~50% of PCD patients have situs inversus.
Young's syndrome	Male infertility (obstructive azoospermia) + rhinosinusitis + bronchiectasis ^[2]. Cause unknown (possibly related to childhood mercury exposure).
Yellow nail syndrome	Triad: yellow dystrophic nails + lymphoedema + exudative pleural effusion ± bronchiectasis ^[2]. Due to lymphatic hypoplasia.
α₁-antitrypsin deficiency	Primarily causes emphysema (panacinar, lower lobe), but associated bronchiectasis is increasingly recognised.

Mnemonic: Congenital Causes of Bronchiectasis

"CF Kids are Young with Yellow nails"

CF = Cystic Fibrosis
Kids (Kartagener's / PCD)
Young (Young's syndrome)
Yellow nails (Yellow nail syndrome)

Category	Examples
Primary humoral immunodeficiency	Common variable immunodeficiency (CVID) — most frequent primary immunodeficiency; late-onset hypogammaglobulinaemia → recurrent sinopulmonary infections → bronchiectasis ^[4]. Also: selective IgA deficiency, X-linked agammaglobulinaemia.
Combined/Phagocyte defects	Chronic granulomatous disease (CGD) — phagocytes lack NADPH oxidase → cannot generate reactive oxygen species → cannot kill catalase-positive organisms (S. aureus, Aspergillus, Nocardia, Serratia) → granuloma formation and bronchiectasis ^[4].
Secondary immunodeficiency	HIV/AIDS ^[2], post-transplant immunosuppression, haematological malignancy.

Why does immunodeficiency cause bronchiectasis? The immune system normally eliminates airway pathogens. When it fails, infections recur and persist → chronic inflammation → structural airway damage → bronchiectasis. This is the "vicious cycle" in action, but the initiating insult is the immune deficit rather than an index infection.

Level	Cause
Luminal	Foreign body aspiration (especially in children — right lower lobe most common due to anatomy of right main bronchus), mucus plugging
Mural	Endobronchial tumour (e.g., carcinoid tumour), severe chronic asthma/COPD
Extramural	Enlarged lymph nodes (e.g., TB lymphadenopathy, lymphoma) compressing bronchus

Mechanism: Obstruction → distal mucus retention → secondary infection → destruction of bronchial wall → localised (often single-lobe) bronchiectasis.

Condition	Mechanism
Rheumatoid arthritis (RA)	"Rheumatoid lung" — lymphocytic bronchiolitis and bronchial inflammation → bronchiectasis. Interestingly, bronchiectasis may precede RA symptoms by years.
Sjögren's syndrome	Lymphocytic infiltration of bronchial glands → sicca of the airways → impaired mucociliary clearance.
Inflammatory bowel disease (IBD)	UC > CD. Large airway inflammation → bronchiectasis. Mechanism uncertain but thought to share embryological origin (foregut).

In interstitial lung disease (ILD) such as idiopathic pulmonary fibrosis (IPF) or post-radiation fibrosis, the surrounding lung parenchyma contracts and fibroses → it literally pulls open the adjacent bronchi → "traction bronchiectasis" ^[2].
This is conceptually different: the bronchial wall is not primarily destroyed by inflammation but is passively dilated by the retracting fibrotic lung.

Up to ~50% of bronchiectasis cases remain idiopathic even after thorough investigation ^[1].

5. Pathophysiology — The Vicious Cycle

This is the central concept you must understand:

Initial insult (any aetiology above) damages the bronchial wall or impairs host defences.
Mucociliary clearance fails — either because cilia are destroyed (post-infectious), dysmotile (PCD), or secretions are too thick (CF), or immune defences fail to control infection.
Mucus pools in dilated airways — the stagnant mucus is an excellent bacterial culture medium.
Bacteria colonise — organisms such as Haemophilus influenzae (most common coloniser), Pseudomonas aeruginosa (associated with more severe disease and worse prognosis), Streptococcus pneumoniae, and Moraxella catarrhalis set up shop.
Neutrophilic inflammation ensues — neutrophils release elastase, matrix metalloproteinases (MMPs), and reactive oxygen species → these destroy the structural components of the bronchial wall (elastin, cartilage).
Structural destruction → permanent dilatation — the wall can no longer maintain its calibre → it balloons out.
The dilated, damaged airway is even worse at clearing mucus → the cycle self-perpetuates and worsens over time.

Bronchial artery hypertrophy: Chronic inflammation stimulates angiogenesis and remodelling of the bronchial arterial circulation (which is systemic pressure). These hypertrophied, tortuous vessels are friable → haemoptysis, which can be massive and life-threatening (bleeding from systemic-pressure vessels).
Airflow obstruction: Luminal mucus + wall thickening + peribronchial fibrosis → obstructive pattern on spirometry. In severe disease with extensive parenchymal destruction and scarring → may also see a restrictive component.
Progressive lung damage: Recurrent infective exacerbations accelerate the cycle → progressive ↓lung function over years → eventual respiratory failure and cor pulmonale.

6. Classification

This is the classical morphological classification based on the appearance of dilated bronchi, best seen on HRCT thorax:

Subtype	Description	Significance
Cylindrical (tubular)	Uniform dilatation of the bronchi; the most common subtype ^[2]. Airways fail to taper normally ("tram-track" sign on axial CT, "signet ring" sign on cross-section).	Mildest form; often earlier disease.
Varicose	Irregular, beaded dilatation with alternating areas of constriction and dilatation (resembles varicose veins).	Intermediate severity.
Cystic (saccular)	Dilated airways terminate in large cystic sacs, often with air-fluid levels.	Most severe form; associated with advanced disease. Cysts may become colonised with Pseudomonas or Aspergillus.
Mixed	Combination of the above patterns in different areas.	Common in clinical practice.

Pattern	Typical Aetiology
Generalised (diffuse, bilateral)	CF, PCD, immunodeficiency, idiopathic
Localised (focal, unilateral or single lobe)	Post-obstructive (FB, tumour), post-infectious (e.g., TB — classically upper lobe; previous pneumonia — any lobe)
Central bronchiectasis	ABPA (pathognomonic)
Upper lobe predominant	Post-TB, CF (late), ABPA
Lower lobe predominant	Idiopathic, PCD (due to gravity — impaired clearance worst in dependent zones), aspiration
Right middle lobe / lingula	NTM infection (Lady Windermere syndrome — classically in thin, elderly women who suppress their cough)

Exam Pearl

Central bronchiectasis = think ABPA until proven otherwise. All other causes typically cause peripheral or diffuse bronchiectasis. The mechanism: the hypersensitivity reaction and mucoid impaction occur in the larger, proximal airways where Aspergillus colonises.

As discussed in Section 4 — always classify by underlying cause (post-infectious, congenital, immune, obstructive, autoimmune, fibrotic, idiopathic).

7. Clinical Features

Symptom	Mechanism	Details
Chronic cough with copious purulent sputum production ^[1]^[2]	Mucus hypersecretion from hypertrophied bronchial glands + impaired clearance in dilated airways → mucus pools and becomes infected (purulent = neutrophils + bacteria).	The hallmark symptom. Sputum is often mucopurulent or frankly purulent, may be foul-smelling (especially if anaerobes are involved). Volume can be substantial (many mL/day). "Large volume, purulent, foul-smelling sputum that increases during postural changes" ^[5] — sputum production characteristically increases on rising in the morning or changing position because gravity redistributes pooled secretions into open airways, triggering cough.
Haemoptysis	Hypertrophied bronchial arteries (systemic pressure) in chronically inflamed airways are friable and can rupture. "Haemoptysis — usually infective" ^[1] — acute infection increases inflammation and vessel fragility.	Ranges from blood-streaked sputum to massive haemoptysis ( > 100–200 mL/day). Bronchiectasis is one of the most common causes of massive haemoptysis (along with TB and lung cancer). Haemoptysis may be the presenting complaint.
Infective exacerbations ^[1]	Baseline bacterial colonisation + any additional insult (viral URTI, new bacterial strain) → acute ↑inflammation → worsening of the vicious cycle.	Presents with: increased sputum volume and purulence, increased dyspnoea, new or worsening haemoptysis, fatigue, and sometimes fever ^[2]. Common exacerbation pathogens: Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, Staphylococcus aureus ^[2].
Dyspnoea	Airflow obstruction (luminal mucus + wall thickening + peribronchial fibrosis) → ↑work of breathing. In severe disease, extensive parenchymal destruction → ↓gas exchange → chronic type II respiratory failure.	Progressive over years; initially exertional, eventually at rest in severe disease.
Weight loss and fatigue ^[1]	Chronic systemic inflammation → catabolic state (↑TNF-α, IL-6) → cachexia. Also chronic infection and frequent exacerbations → poor nutritional intake.	Important constitutional symptom. Significant weight loss should prompt consideration of malignancy or NTM co-infection.
Chest pain ^[1]	Pleuritic pain from pleural irritation adjacent to inflamed/infected bronchiectatic segments. Also musculoskeletal pain from chronic vigorous coughing.	Usually localised.
Rhinosinusitis symptoms	If underlying cause is PCD, CF, or immunodeficiency → the same ciliary/immune defect affects the sinonasal mucosa.	Chronic nasal congestion, post-nasal drip, recurrent sinusitis. This association should prompt investigation for PCD/CF.

Sign	Mechanism	Details
Clubbing ^[2]^[5]	Exact mechanism debated. Likely: megakaryocytes and platelet clumps bypass the pulmonary capillary filter (in bronchiectasis, there are intrapulmonary shunts/anastomoses) and lodge in fingertip capillaries → release PDGF and VEGF → soft tissue hypertrophy and angiogenesis in the nail bed.	Clubbing is a classical finding in bronchiectasis — one of the chronic suppurative lung diseases associated with clubbing (along with lung abscess, empyema, and CF). Not always present but highly suggestive in the right clinical context.
Inspiratory coarse crackles	Air bubbling through secretions in dilated, mucus-filled bronchi during inspiration. "Coarse" because the airways involved are larger (medium-sized bronchi).	Characteristically coarse and may partially clear or change with coughing (unlike fine crackles of ILD which do not change with coughing) ^[2]. Usually bibasal if disease is generalised (most secretions pool in dependent zones). Localised crackles if focal disease.
Expiratory wheeze	Airflow obstruction from mucus plugging + bronchial wall thickening → turbulent flow → wheeze.	Variable; not always present. If prominent, consider overlap with asthma/COPD or ABPA.
Signs of respiratory failure	End-stage bronchiectasis → chronic hypoxaemia → central cyanosis; chronic hypercapnia → CO₂ retention flap, bounding pulse.	Late findings indicating advanced disease.
Signs of cor pulmonale	Chronic hypoxaemia → pulmonary vasoconstriction (hypoxic pulmonary vasoconstriction, HPV) → pulmonary hypertension → right ventricular pressure overload → RV hypertrophy and eventually RV failure.	Elevated JVP, RV heave, loud P2, peripheral oedema, hepatomegaly (from hepatic venous congestion due to right heart failure).
Sputum characteristics on inspection	Classically, if you collect sputum in a container and let it settle, bronchiectatic sputum separates into three layers: (1) frothy top layer, (2) mucopurulent middle layer, (3) purulent sediment at the bottom.	"Bloody mucopurulent sputum: bronchiectasis, lung abscess" ^[5].
Low-grade fever	Chronic bacterial colonisation and intermittent low-level infection → ongoing cytokine release (IL-1, IL-6, TNF-α) → thermoregulatory set-point ↑.	Usually low-grade between exacerbations; higher with acute exacerbation.

Clinical Scenario	Think About
Bronchiectasis + situs inversus + chronic sinusitis + male infertility	Kartagener's syndrome (PCD + situs inversus)
Bronchiectasis + steatorrhoea + recurrent sinusitis + male infertility (Caucasian)	Cystic fibrosis
Bronchiectasis + recurrent sinopulmonary infections + hypogammaglobulinaemia	CVID
Central bronchiectasis + asthma-like symptoms + eosinophilia + high IgE	ABPA
Bronchiectasis + yellow nails + lymphoedema + pleural effusion	Yellow nail syndrome
Bronchiectasis + obstructive azoospermia + rhinosinusitis	Young's syndrome
Bronchiectasis + joint deformities + rheumatoid nodules	Rheumatoid arthritis (rheumatoid lung)
Bronchiectasis + dry eyes + dry mouth	Sjögren's syndrome
Localised bronchiectasis in a child	Foreign body aspiration or post-infectious
Upper lobe bronchiectasis in HK	Post-TB

An acute exacerbation of bronchiectasis is defined clinically by:

Increase in sputum volume and/or purulence ^[2]
Worsening dyspnoea ^[2]
New or worsening haemoptysis ^[2]
Increased fatigue/malaise ^[2]
Fever (may or may not be present)

Common exacerbation pathogens ^[2]:

Haemophilus influenzae (most common overall coloniser)
Streptococcus pneumoniae
Pseudomonas aeruginosa (associated with more frequent exacerbations, more rapid FEV₁ decline, worse prognosis, and higher mortality — this is a very important prognostic organism)
Staphylococcus aureus (especially consider if CF or post-influenza)

High Yield: Pseudomonas in Bronchiectasis

Pseudomonas aeruginosa colonisation is a marker of disease severity and poor prognosis. Patients colonised with Pseudomonas have more frequent exacerbations, faster lung function decline, worse quality of life, and higher mortality. Once isolated, eradication should be attempted, and chronic suppressive therapy may be needed.

Massive haemoptysis is arbitrarily defined as > 100–200 mL/day (some use > 300–600 mL/24h) ^[5]. The danger of massive haemoptysis is death by asphyxia (drowning in your own blood), not by haemodynamic compromise — the total volume lost is often insufficient to cause shock, but even a small volume of blood flooding the alveoli is enough to severely impair gas exchange.

Why does bronchiectasis cause massive haemoptysis?

Chronic inflammation → neovascularisation and hypertrophy of bronchial arteries (systemic pressure, ~120 mmHg) → these tortuous, friable vessels rupture during an infective exacerbation or with erosion.
Treatment: bronchial artery embolisation (BAE) by interventional radiology is the first-line intervention for massive haemoptysis that cannot be controlled medically ^[5].

Initial management priorities ^[5]:

Secure the airway — this is the single most important step.
Lie the patient on the side of the bleeding lung (lateral decubitus position, affected side down) — to protect the unaffected lung from aspiration of blood.
Avoid cough suppressants and sedation (need the patient to cough up blood, not drown in it).
Urgent investigations: CBC, clotting, T&S, ABG, CXR, sputum C/ST + AFB + cytology.
Bronchoscopy to localise the bleeding site.
Bronchial artery embolisation if available.
Surgery (lobectomy/segmentectomy) as last resort for localised disease with uncontrollable bleeding.

High Yield Summary

Definition: Permanent, irreversible dilatation of bronchi due to transmural inflammation and wall destruction.

Vicious Cycle: Impaired clearance → mucus stasis → bacterial colonisation → neutrophilic inflammation → wall destruction → further dilatation → worsened clearance.

Aetiology (HK focus): Post-infectious (especially TB) > idiopathic > immunodeficiency > congenital (CF rare in Chinese). Always exclude treatable causes.

Morphology: Cylindrical (most common) > varicose > cystic (most severe).

Hallmark Presentation: Chronic cough with copious purulent sputum + haemoptysis + coarse inspiratory crackles + clubbing.

Key Associations: Central bronchiectasis = ABPA. Upper lobe = post-TB. Situs inversus = Kartagener's. Yellow nails + lymphoedema + effusion = Yellow nail syndrome.

Exacerbation Pathogens: H. influenzae, S. pneumoniae, P. aeruginosa (worst prognosis), S. aureus.

Haemoptysis Mechanism: Hypertrophied bronchial arteries (systemic pressure) → massive haemoptysis. Treatment: BAE.

GC Slide Emphasis: Mostly idiopathic aetiology; must exclude post-infection and TB; symptoms include chronic sputum/cough, infective exacerbations, haemoptysis (usually infective), weight loss, fatigue, chest pain, dyspnoea.

Active Recall - Bronchiectasis (Definition, Epidemiology, Aetiology, Pathophysiology, Clinical Features)

^[1] GC 052. Fever and purulent sputum.pdf (slide 41 — Bronchiectasis: clinical features) ^[2] Maksim Medicine Notes.pdf (p.303 — Bronchiectasis) ^[3] Adrian Lui Pediatrics Notes.pdf (p.181 — Cystic Fibrosis) ^[4] Jerry's immunodeficiencies.pdf (p.1 — CVID, CGD) ^[5] Ryan Ho Fundamentals.pdf (p.221, 223, 226 — Cough, Dyspnoea, Haemoptysis approach)

Differential Diagnosis of Bronchiectasis

Bronchiectasis presents with a constellation of symptoms — chronic productive cough, purulent sputum, haemoptysis, dyspnoea, and recurrent infective exacerbations — that overlap significantly with many other chronic respiratory (and some non-respiratory) conditions. The challenge is twofold:

Is this really bronchiectasis, or is it something that mimics bronchiectasis? (e.g., COPD, asthma, TB, lung cancer)
If it is bronchiectasis, what is the underlying cause? (The aetiological differential was covered in the previous section.)

Here we focus on condition 1 — the differential diagnosis of conditions that can present similarly to bronchiectasis and how to distinguish them.

GC High Yield — Exam Framing

The GC lecture slide ^[1] and the senior notes ^[6] frame the following as the key differentials for bronchiectasis: Asthma, COPD, TB, chronic rhinosinusitis, interstitial lung disease (ILD), and GERD. The paediatric differential ^[8] additionally includes foreign body aspiration, acute bronchiolitis, primary ciliary dyskinesia, and cystic fibrosis. These are the conditions examiners expect you to discuss.

Detailed Differential Diagnosis Table

Feature	COPD	Bronchiectasis	Why the Difference
Smoking	Classically a smoker ^[6]^[7]	Usually a non-smoker ^[7]	COPD is driven by cigarette smoke-induced inflammation; bronchiectasis is driven by infection/immune/structural defects
Sputum	Mucoid, relatively small volume; purulent only during exacerbations	Copious, purulent, may be foul-smelling, daily	In COPD, mucus hypersecretion occurs but mucociliary clearance is less severely impaired; in bronchiectasis, the dilated airways are chronic bacterial reservoirs
Clubbing	Absent (clubbing in a "COPD patient" should prompt you to think of lung cancer or bronchiectasis overlap)	Present ^[7]	Clubbing is a feature of chronic suppurative lung disease, not simple COPD
Onset	Usually > 40 years, progressive	Symptoms often dating back to childhood or youth ^[7]	COPD requires decades of smoke exposure; bronchiectasis results from earlier insults
CXR	Hyperinflation, flat diaphragms, ↑AP diameter	Tram-line shadows, ring shadows, cystic dilatation ^[7]	Reflects emphysema/air-trapping in COPD vs structural bronchial dilatation in bronchiectasis
Spirometry	Obstructive, incomplete reversibility	Obstructive (can have partial reversibility) or restrictive in severe disease ^[2]	Both have airflow obstruction, but the mechanism differs: COPD = small airway fibrosis + emphysema; bronchiectasis = luminal mucus + wall thickening

Important overlap: There is a well-recognised "COPD-bronchiectasis overlap" — up to 30–50% of COPD patients may have co-existing bronchiectasis on HRCT. "High prevalence of bronchiectasis among patients diagnosed to have COPD" ^[6]. When a COPD patient has frequent purulent exacerbations or Pseudomonas colonisation, suspect co-existing bronchiectasis and obtain HRCT.

Feature	Asthma	Bronchiectasis	Why the Difference
Nature of symptoms	Episodic, variable, with identifiable triggers (allergens, exercise, cold air, viral URTI) ^[3]	Persistent, progressive, not trigger-dependent	Asthma = reversible bronchoconstriction from airway hyperresponsiveness; bronchiectasis = structural, irreversible damage
Sputum	Tenacious, mucoid (not usually purulent unless infective exacerbation); eosinophilic	Copious, purulent, mucopurulent	Asthma inflammation is eosinophilic; bronchiectasis inflammation is neutrophilic
Diurnal variation	Characteristically worse at night/early morning ^[3]	No classical diurnal variation	Asthma is driven by circadian variation in airway tone (↑vagal tone at night)
Reversibility	FEV₁ improves > 12% and > 200 mL post-bronchodilator	Partial or no reversibility	Asthma = smooth muscle spasm (reversible); bronchiectasis = structural wall damage (fixed)
Atopy	Common: eczema, allergic rhinitis, ↑IgE, ↑eosinophils	Not typical (unless ABPA is the cause)	Asthma is fundamentally an atopic/Th2-mediated disease
HRCT	Normal airway calibre (no dilatation)	Bronchial dilatation — "diagnosed by CXR/HRCT demonstrating airway dilatation ('tram-line' appearance)" ^[3]	Definitive differentiator

"Asthma affects up to 10% of bronchiectasis patients" ^[6] — these conditions can co-exist. A patient with "asthma" who produces copious purulent sputum daily and has clubbing should have HRCT to exclude bronchiectasis.

D/Dx of Generalised Wheeze

From the paediatric lecture ^[3]: D/dx of generalised wheeze includes bronchiectasis, bronchiolitis obliterans, and viral bronchiolitis (in children). D/dx of localised wheeze: tumour and foreign body. This is a high-yield framing for paediatric and GC exams.

Feature	TB	Bronchiectasis	Why the Difference
Sputum	Blood-streaked (classic) ^[9]; may be mucoid or purulent in cavitary disease	Mucopurulent, copious, ± haemoptysis	TB haemoptysis comes from caseous necrosis eroding into pulmonary vessels; bronchiectasis haemoptysis from hypertrophied bronchial arteries
Constitutional symptoms	Afternoon/evening fevers, drenching night sweats, significant weight loss	Low-grade fever, weight loss, fatigue (less dramatic)	TB provokes a strong Th1 immune response with cytokine-driven systemic symptoms
CXR	Upper lobe infiltrates, cavitation, calcified granulomata, Ghon focus/Ranke complex	Tram-lines, ring shadows, cystic changes	Reflects different pathology: granulomatous necrosis vs bronchial dilatation
Microbiology	AFB smear +, TB culture +, GeneXpert MTB/RIF +	Sputum C/ST grows typical colonisers (H. influenzae, Pseudomonas)	Definitive microbiological distinction

Critical point for Hong Kong practice: TB is both a differential diagnosis and a common cause of bronchiectasis (post-TB bronchiectasis). "Needs to exclude other causes, e.g. post-infection and TB" ^[1]. A patient with upper-lobe bronchiectasis in HK must have TB actively excluded with sputum AFB ×3, culture, and possibly GeneXpert.

Feature	Lung Cancer	Bronchiectasis	Why the Difference
Age/Smoking	Typically > 50 years, heavy smoker	Any age, usually non-smoker	Smoking-related carcinogenesis vs infection/immune-mediated
Haemoptysis	Blood-streaked sputum ^[9], may be massive with erosion into great vessels	Bloody mucopurulent sputum ^[9]	Cancer: neovascular tumour vessels bleed; bronchiectasis: hypertrophied bronchial arteries
Weight loss	Severe, progressive, disproportionate to apparent disease burden	Present but usually less dramatic	Cancer cachexia from tumour-derived factors (TNF-α/cachectin, PIF)
Signs	Clubbing, cervical/supraclavicular lymphadenopathy, Horner's syndrome, SVCO ^[10]^[11]	Clubbing ^[10]^[11]; no lymphadenopathy, no Horner's	Cancer causes regional invasion and distant spread; bronchiectasis is an airway disease
CXR/CT	Mass lesion, hilar lymphadenopathy, pleural effusion, bony mets	Bronchial dilatation, no discrete mass	Completely different radiological pattern

Exam Pearl — Clubbing Differential

Clubbing with haemoptysis: Think lung cancer, bronchiectasis, lung abscess, or empyema ^[10]^[11]. The presence of cervical and supraclavicular lymphadenopathy, Horner's syndrome, or SVCO swings the diagnosis heavily towards malignancy.

Feature	Lung Abscess	Bronchiectasis
Sputum	Foul-smelling, dark-coloured (anaerobes) ^[5]; large volume when abscess ruptures into bronchus	Purulent, foul-smelling if anaerobes present, but chronically produced
Onset	Often subacute (weeks) following aspiration event, dental procedure, or pneumonia	Chronic (months to years)
Imaging	CXR/CT: thick-walled cavity with air-fluid level, usually single	Multiple dilated airways ± air-fluid levels in cystic bronchiectasis
Risk factors	Aspiration risk (alcoholism, ↓consciousness, poor dentition, dysphagia)	Post-infectious, immune deficiency, congenital

Feature	ILD	Bronchiectasis
Cough	Dry, non-productive	Productive with copious purulent sputum
Crackles	Fine, late-inspiratory, "Velcro-like" — do NOT change with coughing	Coarse, inspiratory — may partially clear with coughing ^[2]
Clubbing	Present (especially in IPF)	Present
Spirometry	Restrictive (↓FVC, normal or ↑FEV₁/FVC ratio)	Obstructive (or mixed in severe disease)
HRCT	Ground-glass opacities, reticular pattern, honeycombing, traction bronchiectasis	True bronchial dilatation with wall thickening, mucus plugging

Key concept — Traction bronchiectasis: In ILD, the fibrotic lung parenchyma contracts and pulls open adjacent bronchi → "traction bronchiectasis." This is mechanically different from true bronchiectasis (where the wall is destroyed by inflammation). On HRCT, traction bronchiectasis occurs in areas of established fibrosis and lacks the mucus plugging and wall thickening of infective bronchiectasis.

Feature	GERD-related Cough	Bronchiectasis
Mechanism	Micro-aspiration of gastric acid → chemical airway irritation + vagal reflex from oesophageal acid → cough	Structural airway damage → mucus retention → infection
Sputum	Usually dry or minimal sputum	Copious purulent sputum
Timing	Worse post-prandially, on lying flat	No meal-related pattern
Heartburn/regurgitation	Typically present	May co-exist (GERD can worsen bronchiectasis)
HRCT	Normal airways	Bronchial dilatation

"GERD" is listed as a differential ^[6] and also a co-morbidity — chronic aspiration from GERD can both cause and exacerbate bronchiectasis, especially in the dependent lower lobes.

"Affects up to 60% of cases with bronchiectasis" ^[6] — this is frequently a co-existing condition rather than a true differential.
Post-nasal drip causes chronic cough (drip irritates the larynx/pharynx → cough reflex), but the cough is usually non-productive or mildly productive of mucoid secretions, not copious purulent sputum.
In PCD and CF, sinusitis and bronchiectasis co-exist because the same ciliary/mucus defect affects both the sinonasal and tracheobronchial mucosa.

Feature	Foreign Body	Bronchiectasis
History	Acute choking episode, often witnessed; unilateral symptoms	Chronic, progressive
Wheeze	Localised, unilateral ^[8]	Generalised or localised depending on distribution
Age	Typically toddlers (1–3 years)	Any age
Imaging	Expiratory CXR: unilateral hyperinflation (air trapping distal to FB) ^[8]; CT may show FB	HRCT: bronchial dilatation

"Expiratory CXR should be taken when foreign body aspiration is suspected since the unilateral hyperinflation may be more apparent on the expiratory film" ^[8]. If a FB is missed and remains lodged, it causes post-obstructive bronchiectasis (localised, distal to the FB) — so an unresolved FB is actually an aetiology of bronchiectasis.

Feature	Bronchiolitis Obliterans	Bronchiectasis
Level of disease	Small airways (bronchioles) — submucosal and peribronchiolar fibrosis → luminal narrowing ^[7]^[8]	Medium-sized bronchi — wall destruction → dilatation
Sputum	Usually dry cough or minimal sputum	Copious purulent sputum
Associations	Post-viral infection, autoimmune disease, post-lung/bone marrow transplant, inhalational injury ^[8]	Post-infectious, immunodeficiency, congenital
Reversibility	Irreversible with inhaled bronchodilators ^[8]	Partially or non-reversible
HRCT	Mosaic attenuation pattern (air trapping), no bronchial dilatation	Bronchial dilatation

"Due to luminal or extraluminal masses compressing onto central airways. Associated with exertional dyspnoea ± monophonic wheezes. Spirometry also shows obstructive pattern but flow-volume loop is characteristic for upper airway obstruction (expiratory plateau)" ^[3].

The key differentiator is the flow-volume loop: central/upper airway obstruction produces a flattened inspiratory curve, flattened expiratory curve, or both (depending on whether the obstruction is fixed, variable intrathoracic, or variable extrathoracic). This is very different from the "scooped out" concave expiratory curve of diffuse intrathoracic obstruction (asthma/COPD).
Central airway obstruction causes monophonic wheeze (single pitch, because one large airway is narrowed at one point) vs. polyphonic wheeze in asthma/COPD (multiple small airways narrowed to varying degrees).

Feature	CHF	Bronchiectasis
Sputum	Pink, frothy (pulmonary oedema fluid) ^[9]	Purulent, mucopurulent
Dyspnoea pattern	Orthopnoea, PND, worse lying flat	Positional sputum production (worse lying on affected side), but no classical orthopnoea
Crackles	Fine, bibasal (fluid in alveoli)	Coarse (secretions in dilated bronchi)
CXR	Cardiomegaly, upper lobe diversion, Kerley B lines, bat-wing pulmonary oedema	Tram-lines, ring shadows
BNP	Elevated	Normal

Condition	Sputum Character	Clubbing	Key Imaging	Key Test
Bronchiectasis	Copious, purulent, ± foul	Yes	HRCT: bronchial dilatation	HRCT thorax
COPD	Mucoid, small volume	No	CXR: hyperinflation	Spirometry: irreversible obstruction
Asthma	Mucoid, tenacious	No	CXR: usually normal	Spirometry: reversible obstruction; FENO ↑
TB	Blood-streaked	Rare	CXR: upper lobe infiltrate/cavity	AFB smear, culture, GeneXpert
Lung cancer	Blood-streaked	Yes	CXR/CT: mass	Biopsy (bronchoscopy/CT-guided)
Lung abscess	Foul, dark	Possible	CXR: cavity + air-fluid level	CT thorax + sputum culture
ILD	Dry	Yes (IPF)	HRCT: GGO, honeycombing	Spirometry: restrictive; DLCO ↓
CHF	Pink, frothy	No	CXR: cardiomegaly, oedema	BNP, echocardiography

High Yield Summary

Top differentials to exclude in a patient with suspected bronchiectasis:

COPD — smoker, mucoid sputum, no clubbing, irreversible obstruction; overlap common (up to 50%).
Asthma — episodic, trigger-related, reversible, eosinophilic; can co-exist with bronchiectasis.
Tuberculosis — must actively exclude in HK; both a differential AND the most common identifiable cause.
Lung cancer — especially in smokers with haemoptysis; look for lymphadenopathy, mass on imaging.
ILD — dry cough, fine crackles, restrictive spirometry; traction bronchiectasis ≠ true bronchiectasis.
GERD — co-morbidity and exacerbating factor; post-prandial cough, no purulent sputum.
Foreign body (children) — acute onset, localised wheeze, expiratory film shows air trapping.

The definitive test to confirm bronchiectasis and exclude mimics is HRCT thorax.

GC slide emphasis: Cause is mostly idiopathic — must exclude post-infection and TB ^[1]. Sputum character is key: bloody mucopurulent = bronchiectasis/abscess; blood-streaked = TB/cancer; pink frothy = pulmonary oedema ^[9].

Active Recall - Differential Diagnosis of Bronchiectasis

References

^[1] Lecture slides: GC 052. Fever and purulent sputum.pdf (slide 41 — Bronchiectasis: clinical features) ^[2] Senior notes: Maksim Medicine Notes.pdf (p.303 — Bronchiectasis) ^[3] Senior notes: Adrian Lui Pediatrics Notes.pdf (p.170, p.172 — Asthma D/Dx) ^[5] Senior notes: Ryan Ho Fundamentals.pdf (p.221 — Cough approach, sputum characteristics) ^[6] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p.181, p.183 — Bronchiectasis differential diagnosis) ^[7] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p.220 — COPD differential diagnosis) ^[8] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p.176 — Obstructive lung pattern and asthma D/Dx) ^[9] Senior notes: learning_points_output.txt (Respiratory — Four Cases of Haemoptysis learning points) ^[10] Lecture slides: General clerkship Teaching Clinic - Haemoptysis.pdf (p.48 — Physical signs in haemoptysis) ^[11] Lecture slides: Respiratory Four cases of Haemoptysis.pdf (p.43 — Physical signs in haemoptysis)

Diagnostic Criteria, Diagnostic Algorithm, and Investigation Modalities

Unlike many conditions (e.g., rheumatoid arthritis, SLE), bronchiectasis does not have a formal set of "classification criteria" with point scores. Instead, the diagnosis is clinico-radiological — it requires:

Compatible clinical syndrome: Chronic productive cough (typically with purulent sputum), ± haemoptysis, ± recurrent infective exacerbations, ± dyspnoea.
Radiological confirmation on HRCT thorax demonstrating permanent bronchial dilatation (the gold-standard investigation) ^[1]^[2]^[6]^[12].

The diagnosis of bronchiectasis is confirmed by HRCT thorax, not by CXR, not by spirometry, and not by clinical features alone. CXR may be normal in up to 50% of cases ^[5]^[12].

Once bronchiectasis is confirmed radiologically, the second diagnostic task is to identify the underlying aetiology (since bronchiectasis is a final common pathway, not a standalone diagnosis). This requires a systematic battery of aetiological investigations.

GC High Yield — Investigations from Lecture Slide

GC 052 lists the following investigations for bronchiectasis ^[1]:

CXR — may be normal or tramline shadows
HRCT thorax
Immunoglobulins
Auto-antibodies
Barium studies or 24h oesophageal pH monitoring
Ciliary and sperm analysis
Sputum culture and AFB
Neutrophil functions
Sweat test

This is a high-yield list for in-house exams — it essentially represents the "aetiological workup" checklist.

The clinical approach proceeds in three phases: (A) suspect bronchiectasis clinically → (B) confirm radiologically → (C) investigate the underlying aetiology.

3. Investigation Modalities — Detailed Breakdown

A. Investigations for Diagnosis (Confirming Bronchiectasis)

CXR may be normal or show tramline shadows ^[1].

CXR Finding	What It Represents	Pathophysiological Basis
Ring shadows ( < 1 cm) ^[2]^[5]^[6]^[12]	Dilated bronchi seen end-on ^[5]	When you look down the barrel of a dilated bronchus on a PA film, the thickened wall appears as a small ring. Also described as "bunch of grapes" appearance in clustered cystic bronchiectasis ^[6].
Tramline shadows ^[2]^[5]^[6]^[12]	Dilated bronchi seen from the side ^[5] — "parallel line" appearance ^[6]	Two thick white parallel lines separated by a black (air-filled) lumen. Normal bronchi are too small to see on CXR; when dilated and thick-walled, they become visible.
Tubular shadows (rare) ^[5]^[12]	Bronchi filled with secretions ^[5]	When a dilated bronchus is completely filled with mucus/pus, it appears as a solid white tube (no air-filled lumen visible).
Air-fluid levels	Fluid (pus/mucus) pooling in cystic bronchiectasis	Gravity causes secretions to layer in dependent portions of large cystic spaces.
Segmental collapse ^[2]	Mucus plugging causing distal atelectasis	Complete obstruction of a bronchus by inspissated secretions → resorption of distal air → collapse.
Irregular peripheral opacities ^[6]	Mucopurulent plugs in peripheral airways	Mucus plugging the small airways creates opacified segments visible on plain film.

Key Limitation of CXR

CXR is only abnormal in ~50% of bronchiectasis cases ^[5]^[12]. A normal CXR does NOT exclude bronchiectasis. If clinical suspicion exists, proceed directly to HRCT. CXR is useful mainly to exclude other pathology (e.g., mass, effusion, consolidation) and as a baseline.

HRCT thorax is the definitive investigation for diagnosing bronchiectasis ^[1]^[2]^[5]^[6]^[12]^[13].

Why HRCT and not standard CT? HRCT uses thin slices (1–1.5 mm) with a high-spatial-frequency reconstruction algorithm. As Felix Lai's notes explain: "sacrifice spatial volume for higher resolution — look at airways and vessels better" ^[6]. This allows you to see the fine detail of airway walls and their relationship to adjacent pulmonary arteries. Standard CT uses thicker slices (5–10 mm) and may miss early or subtle bronchiectasis.

Diagnostic HRCT Criteria for Bronchiectasis:

The diagnosis rests on demonstrating bronchial dilatation using one or more of the following signs:

HRCT Sign	Description	Pathophysiological Basis
"Signet ring" sign ^[6]^[12]	In cross-section, a dilated air-filled bronchus sits next to its companion pulmonary artery. The bronchus (larger, dark) = the ring; the artery (smaller, white) = the "jewel/stone on the ring." Bronchoarterial ratio > 1 (normally the bronchus and artery are roughly the same diameter) ^[12].	In health, the bronchial lumen matches the diameter of the adjacent artery. Destruction of the bronchial wall → dilatation → the bronchus becomes larger than its paired artery.
Lack of peripheral tapering ^[2]^[6]^[12]	Bronchi normally taper as they branch distally. In bronchiectasis, they maintain the same calibre (or even widen) as they extend towards the periphery. Specifically: no tapering > 2 cm from hilum in the middle third ^[5]^[12]; visible airways within 1 cm of the pleural surface ^[12] (normally bronchi are not visible this peripherally).	Loss of cartilage and elastic tissue → the wall cannot constrict as the airway branches → no tapering.
Bronchial wall thickening ^[6]^[12]	The bronchial wall appears thicker than normal (> 50% of the artery diameter in some criteria). Corresponds to the ring shadows seen on CXR ^[12].	Chronic transmural inflammation → oedema, granulation tissue, fibrosis of the wall → thickening.

Additional HRCT Findings:

Finding	Description	Significance
Mucus plugging ^[5]^[6]^[12]	Dilated bronchi filled with secretions appear as solid opacities. On mediastinal window, mucus appears darker than the airway wall (helps distinguish from blood vessels) ^[5]^[12].	Impaired mucociliary clearance → secretions accumulate in dilated airways.
"Tree-in-bud" pattern ^[6]^[12]	Peripheral irregular short linear branching opacities, like a tree with buds at the ends. "Refers to peripheral irregular short linear branching indicating inspissated secretions" ^[6].	Small airway mucus plugging and peribronchiolar inflammation. Seen in the lung periphery. Not specific to bronchiectasis (also seen in TB, NTM, endobronchial spread of infection).
Air-fluid levels within cystic dilatation ^[12]	Visible fluid layering in dependent portions of large cysts.	Hallmark of cystic (saccular) bronchiectasis — the most severe morphological subtype.
Mosaic attenuation on expiratory images ^[12]	Patchy areas of differing lung density on expiratory-phase CT. The relatively lucent (dark) areas represent air trapping (small airways obstructed → air cannot exit during expiration).	Small airway disease accompanying the large airway dilatation. Not specific (also seen in bronchiolitis obliterans, asthma).
Atelectasis, consolidation, abscess ^[12]	Parenchymal changes around bronchiectatic airways.	Secondary to mucus plugging (atelectasis), spill-over infection (consolidation), or severe infection (abscess).
Cysts clustered like grapes ^[6]	In heavily involved areas, cystic bronchiectasis produces clusters of cysts off the bronchial wall.	End-stage destruction — bronchi terminate in large sacs rather than tapering to bronchioles.

Distribution Pattern on HRCT — Clues to Aetiology:

Distribution	Aetiology to Consider
Central (perihilar)	Allergic bronchopulmonary aspergillosis (ABPA) ^[6]
Upper lobe predominant	Cystic fibrosis, post-TB, post-radiation fibrosis ^[6]
Middle lobe / lingula predominant	Primary ciliary dyskinesia, non-tuberculous mycobacterium infection ^[6] (Lady Windermere syndrome)
Lower lobe predominant	Idiopathic, chronic recurrent aspiration ^[6]
Localised (single lobe/segment)	Post-obstructive (foreign body, tumour, lymph node), post-infectious (focal pneumonia)
Diffuse bilateral	CF, PCD, immunodeficiency, idiopathic

Exam Pearl — The Signet Ring Sign

The signet ring sign is the single most important HRCT finding to recognise for bronchiectasis. It proves that the bronchial lumen is abnormally dilated relative to its companion pulmonary artery. In cross-section: large dark ring (dilated bronchus) + small white dot (artery) = "jewel on the ring." Bronchoarterial ratio > 1 is diagnostic ^[12].

"Obstructive pattern is the most frequent finding" ^[6].

Parameter	Finding	Explanation
FEV₁	↓	Airflow obstruction from mucus plugging + bronchial wall thickening + peribronchial fibrosis
FVC	Normal or ↓	Normal in pure obstruction; ↓ if severe disease with scarring, atelectasis, or parenchymal destruction → mixed obstructive-restrictive pattern ^[2]^[12]
FEV₁/FVC ratio	↓ (obstructive pattern)	Defines airflow obstruction
Reversibility	May be partially reversible ^[2]	Some component of mucus and bronchospasm is reversible; structural damage is not
DLCO	May be ↓ in severe disease	Loss of alveolar-capillary surface area from parenchymal destruction

Why can bronchiectasis sometimes show a reversible pattern? Mucus plugging and co-existing bronchospasm (particularly in ABPA or asthma-bronchiectasis overlap) contribute a reversible component. This does NOT mean the underlying bronchiectasis is reversible — the structural dilatation is permanent.

Spirometry is not diagnostic for bronchiectasis (many conditions cause obstructive spirometry). Its role is to functionally assess the degree of impairment and provide a baseline for monitoring disease progression ^[6].

Investigation	Purpose	Key Findings
Sputum culture and sensitivity (C/ST) ^[1]^[12]	Identify colonising organisms, guide antibiotic choice	H. influenzae (most common), P. aeruginosa (marker of severity), S. pneumoniae, M. catarrhalis, S. aureus
Sputum AFB smear/culture ^[1]^[12]	Exclude active TB; detect non-tuberculous mycobacteria (NTM, especially MAC)	AFB+ on smear → high bacterial load (TB or NTM); culture identifies species and drug susceptibility
Pulse oximetry / ABG ^[6]^[13]	Assess oxygenation and ventilation	SpO₂ < 92% → consider ABG; Type I RF (↓PaO₂, normal/↓PaCO₂) in moderate disease; Type II RF (↓PaO₂, ↑PaCO₂) in severe/end-stage disease
CBC with differential ^[6]	Leukocytosis during exacerbation; eosinophilia suggests ABPA; anaemia of chronic disease	Leukocytosis ^[6] during infective exacerbation; ↑eosinophils + ↑IgE → suspect ABPA ^[12]
CRP / ESR	Inflammatory markers; baseline and during exacerbations	Elevated during exacerbation; chronically mildly elevated in severe disease

This is critical — bronchiectasis is a consequence, not a primary disease. The GC lecture slide ^[1] provides a comprehensive aetiological investigation list.

Investigation	What It Tests For	Rationale (First Principles)	Expected Findings if Positive
Immunoglobulins (IgG, IgA, IgM) ^[1]^[6]^[12]	Immunodeficiency syndromes (especially CVID) ^[4]	Antibodies are the primary defence against encapsulated bacteria in the airways. Deficiency → recurrent sinopulmonary infections → bronchiectasis. CVID is the most common primary immunodeficiency ^[4].	↓IgG ± ↓IgA ± ↓IgM (panhypogammaglobulinaemia in CVID)
Serum IgE + specific IgE to Aspergillus fumigatus ^[12]	ABPA	ABPA is a Th2/IgE-mediated hypersensitivity to Aspergillus → central bronchiectasis. Total IgE is typically very high ( > 1000 IU/mL).	↑↑ total IgE, positive specific IgE and/or skin prick test to Aspergillus, ↑eosinophils, precipitating IgG antibodies to Aspergillus
Auto-antibodies (RF, anti-CCP, ANA, ANCA) ^[1]^[12]	Autoimmune/CTD-associated bronchiectasis (RA, Sjögren's, vasculitis)	Autoimmune inflammation can target bronchial walls. RA is the most common CTD association.	RF+/anti-CCP+ (RA); ANA+/anti-Ro/La+ (Sjögren's); ANCA+ (vasculitis)
Sweat test (sweat chloride) / CFTR mutation analysis ^[1]^[6]^[12]	Cystic fibrosis	CFTR dysfunction → impaired Cl⁻ reabsorption in sweat ducts → abnormally high sweat Cl⁻. "Sweat test involves using pilocarpine (muscarinic agonist) to induce sweating. Chloride content is then tested. CF patients have abnormally high Cl⁻ level" ^[12].	Sweat Cl⁻ > 60 mmol/L is diagnostic; 30–59 mmol/L is borderline → proceed to CFTR genetic testing
Ciliary and sperm analysis ^[1]^[12]	Primary ciliary dyskinesia (PCD)	PCD = dysmotile/immotile cilia due to dynein mutations → impaired mucociliary clearance + immotile sperm. Diagnosis requires demonstrating abnormal ciliary structure (electron microscopy of nasal brush biopsy) and/or ciliary beat frequency/pattern (high-speed video microscopy).	Abnormal ciliary ultrastructure (absent outer/inner dynein arms); abnormal beat frequency/pattern; ↓nasal NO (screening test) ^[3]
Serum alpha-1 antitrypsin (A1AT) level ^[1]^[6]	Alpha-1 antitrypsin deficiency	A1AT normally neutralises neutrophil elastase in the lungs. Deficiency → unopposed elastase → destruction of lung parenchyma (emphysema) and bronchial walls (bronchiectasis).	↓A1AT level; confirm with phenotyping (PiZZ homozygote = severe deficiency)
Barium swallow / 24h oesophageal pH monitoring ^[1]^[12]	GERD / chronic aspiration	Repeated micro-aspiration of gastric contents → chemical injury and infection of lower airways → bronchiectasis (especially lower lobe).	Barium swallow: reflux/aspiration on fluoroscopy. 24h pH: ↑oesophageal acid exposure time (DeMeester score > 14.72)
Neutrophil function tests ^[1]	Chronic granulomatous disease (CGD)	CGD = phagocytes lack NADPH oxidase → cannot generate reactive oxygen species → cannot kill catalase-positive organisms → granuloma formation + bronchiectasis ^[4].	Low dihydrorhodamine (DHR) reduction test or abnormal nitroblue tetrazolium (NBT) test — these test the oxidative burst of neutrophils
Bronchoscopy ^[6]^[12]^[13]	Rule out endobronchial lesion (tumour, FB) in localised disease; obtain BAL for microbiology (NTM) when sputum non-diagnostic	If bronchiectasis is localised to one lobe/segment, an obstructing lesion (carcinoid tumour, foreign body, lymph node) must be excluded. BAL provides a more concentrated sample for mycobacterial culture than expectorated sputum.	Endobronchial mass → biopsy for histology. BAL: AFB culture for NTM; fungal culture for Aspergillus

When to Investigate for Aetiology

Aetiological screening is particularly important if ^[12]:

Patient is young ( < 50 years)
Clinical course is deteriorating despite treatment
Distribution is unusual (e.g., central → ABPA; upper lobe → TB/CF)
Associated features suggest a systemic condition (e.g., sinusitis + infertility → PCD; joint symptoms → RA)

In practice, most centres recommend at minimum: immunoglobulins, total IgE + Aspergillus-specific IgE, sputum AFB, and auto-antibodies for all new diagnoses. Additional tests (sweat test, ciliary analysis, A1AT, neutrophil function) are guided by clinical suspicion.

Scenario	Investigation	Rationale
Massive haemoptysis	CT angiography / bronchial arteriogram ^[5]	Identify the source and anatomy of hypertrophied bronchial arteries prior to bronchial artery embolisation (BAE)
Suspected NTM infection	Sputum AFB culture ×3 (including liquid culture, e.g., BACTEC); bronchoscopy + BAL if sputum non-diagnostic	NTM (especially MAC) are slow-growing; multiple samples and prolonged culture are needed for diagnosis
Pre-surgical assessment	CT thorax with contrast + spirometry + ABG + V/Q scan or DLCO	Assess operability — sufficient residual lung function after resection?
Suspected cor pulmonale	Echocardiography	Estimate pulmonary artery systolic pressure (PASP); assess RV function
Recurrent exacerbations with P. aeruginosa	Sputum C/ST at each exacerbation + when stable (to confirm chronic colonisation)	Guide eradication attempts and chronic suppressive antibiotic therapy

For a newly diagnosed bronchiectasis patient, the systematic workup can be summarised:

Category	Investigations
Confirm diagnosis	HRCT thorax (gold standard)
Baseline severity	Spirometry, SpO₂/ABG, CBC, CRP, sputum C/ST + AFB
Aetiological screen	Immunoglobulins (IgG, IgA, IgM), total IgE + specific IgE Aspergillus, auto-antibodies (RF, anti-CCP, ANA, ANCA), sputum AFB ×3
Guided by clinical suspicion	Sweat test/CFTR (if young, Caucasian, or suggestive features), ciliary/sperm analysis (if sinusitis + male infertility), A1AT level, 24h pH study, neutrophil function tests, bronchoscopy (if localised)
Monitoring	Serial spirometry (annual), sputum C/ST at exacerbations, CXR/HRCT as clinically indicated

High Yield Summary

Diagnostic gold standard: HRCT thorax — look for the signet ring sign (bronchoarterial ratio > 1), lack of peripheral tapering, bronchial wall thickening, mucus plugging, tree-in-bud pattern.

CXR sensitivity is only ~50% — normal CXR does NOT exclude bronchiectasis. Classic CXR signs: tram-lines, ring shadows, tubular shadows.

Spirometry: Obstructive pattern most common (↓FEV₁, ↓FEV₁/FVC); may be mixed in severe disease. Used for functional assessment, not diagnosis.

Distribution on HRCT gives aetiological clues: Central = ABPA. Upper lobe = CF/post-TB. Middle lobe = PCD/NTM. Lower lobe = idiopathic/aspiration.

GC lecture slide investigation list ^[1]: CXR, HRCT, immunoglobulins, auto-antibodies, barium/24h pH, ciliary and sperm analysis, sputum C/ST + AFB, neutrophil functions, sweat test.

Aetiological workup is mandatory — bronchiectasis is a final common pathway. Always ask "Why does this patient have bronchiectasis?"

Active Recall - Bronchiectasis Investigations and Diagnosis

References

^[1] Lecture slides: GC 052. Fever and purulent sputum.pdf (slide 43 — Bronchiectasis: investigations) ^[2] Senior notes: Maksim Medicine Notes.pdf (p.303 — Bronchiectasis) ^[3] Senior notes: Adrian Lui Pediatrics Notes.pdf (p.183 — PCD) ^[4] Senior notes: Jerry's immunodeficiencies.pdf (p.1, p.3 — CVID, CGD) ^[5] Senior notes: Ryan Ho Fundamentals.pdf (p.239 — CXR bronchiectasis features) ^[6] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p.182–185 — Bronchiectasis diagnosis, radiological tests) ^[12] Senior notes: Ryan Ho Respiratory.pdf (p.130–131 — Bronchiectasis Ix, HRCT features, screening tests) ^[13] Lecture slides: Respiratory Four cases of Haemoptysis.pdf (p.45 — Important investigations)

Management of Bronchiectasis

The management of bronchiectasis is built around breaking the vicious cycle that drives the disease:

Treat the underlying cause (if identifiable and treatable) — the only way to truly interrupt the cycle at its origin.
Enhance airway clearance — remove the pooled mucus that feeds bacterial colonisation.
Treat and prevent infection — reduce the bacterial burden that drives neutrophilic inflammation.
Reduce inflammation — limit protease-mediated structural damage.
Manage complications — haemoptysis, respiratory failure, cor pulmonale.
Surgery — for refractory localised disease or life-threatening haemoptysis.

Think of it as attacking every node of the vicious cycle: clearance failure → mucus stasis → infection → inflammation → wall destruction. Each treatment arm targets one or more nodes.

GC High Yield — Management Framework

From the GC lecture slide ^[1]: The management investigation list implies the management philosophy — identify the cause (immunoglobulins, sweat test, auto-antibodies, etc.), then treat accordingly. Maksim Medicine Notes ^[2] and Ryan Ho Respiratory ^[12] provide the most comprehensive management algorithms in the senior notes.

Detailed Treatment Modalities

This is the first and most important step — if you can remove the initiating insult, you can slow or halt the vicious cycle. Unfortunately, most cases are idiopathic ^[1], but the treatable causes must be identified and addressed.

Aetiology	Treatment	Mechanism / Rationale
ABPA	Systemic corticosteroids + itraconazole (antifungal) ^[2]	Steroids suppress the Th2/IgE-mediated hypersensitivity driving the inflammation; itraconazole ("itra" = intra, "conazole" = azole antifungal that inhibits ergosterol synthesis in fungal cell membranes) reduces Aspergillus fungal burden → ↓antigenic stimulus.
CVID / Immunodeficiency	Intravenous immunoglobulin (IVIG) replacement ^[4]	Replaces the deficient antibodies (IgG) → restores opsonisation and complement activation → ↓frequency and severity of sinopulmonary infections. Typically given every 3–4 weeks lifelong.
GERD / Chronic aspiration	PPI ± fundoplication ^[2]	PPI (proton pump inhibitor, e.g., omeprazole) blocks the gastric H⁺/K⁺-ATPase → ↓gastric acid → ↓chemical injury from aspiration. Fundoplication (surgical wrapping of gastric fundus around lower oesophageal sphincter) mechanically prevents reflux.
NTM infection	Triple antibiotic therapy: macrolide + rifampicin + ethambutol ^[2]^[12]	NTM (especially MAC) require prolonged multi-drug therapy (≥12 months after culture conversion) because they grow intracellularly within macrophages and have innate resistance to many antibiotics. Macrolide (e.g., azithromycin) is the backbone.
Post-obstructive (FB, tumour)	Remove the obstruction (bronchoscopic FB retrieval, tumour resection/debulking)	Removing the obstruction restores distal airway drainage → prevents further mucus retention and infection.
CGD	Septrin (co-trimoxazole) prophylaxis + itraconazole prophylaxis ± HSCT ^[4]	Septrin provides prophylaxis against catalase-positive bacteria; itraconazole prevents Aspergillus infection. HSCT (haematopoietic stem cell transplant) is curative — replaces defective phagocytes with functional donor cells.
CF	CFTR modulators (e.g., elexacaftor/tezacaftor/ivacaftor — Trikafta), airway clearance, pancreatic enzyme replacement	CFTR modulators correct the underlying protein defect → improve Cl⁻ channel function → thinner secretions. This is a disease-modifying therapy that has dramatically improved outcomes in eligible CF genotypes.

Only Some Causes Are Treatable

"Only some causes are treatable" ^[2] — post-infectious bronchiectasis (e.g., post-TB, post-measles) represents permanent structural damage. You cannot reverse it. The focus in these patients shifts entirely to Steps 2–6: maintenance, exacerbation management, and complication prevention.

B. Long-Term Maintenance Therapy (All Patients)

This is the cornerstone of bronchiectasis management — the single most important non-pharmacological intervention. The rationale is straightforward: if mucus pools in dilated airways and feeds the infection-inflammation cycle, physically removing that mucus breaks the cycle.

Technique	Description	Mechanism
Postural drainage ^[2]	Patient positioned so that the affected lung segment is uppermost, using gravity to drain secretions towards central airways where they can be coughed out.	Gravity-dependent drainage. Example: lower lobe bronchiectasis → patient lies prone with head tilted down.
Chest percussion / clapping ^[2]	Rhythmic clapping on the chest wall over the affected area (with cupped hands or mechanical percussor).	Mechanical vibration loosens thick, adherent mucus from bronchial walls → facilitates mobilisation into larger airways.
Active cycle of breathing technique (ACBT)	Three phases: (1) breathing control (relaxed breathing), (2) thoracic expansion exercises (deep breaths), (3) forced expiration technique ("huffing").	Deep inspiration expands airways behind mucus plugs → huffing creates high-velocity airflow in open glottis → shears mucus off airway walls. Less fatiguing than sustained coughing.
Positive expiratory pressure (PEP) devices	Patient exhales against resistance (e.g., Flutter valve, Acapella device).	Creates back-pressure that splints open collapsing airways → air gets behind mucus plugs → mucus is mobilised centrally. Oscillatory PEP devices also vibrate the airway walls.
Nebulised hypertonic saline (6–7%) ^[2]	Inhaled before airway clearance sessions.	Osmotically draws water into the airway lumen → hydrates and loosens thick, tenacious secretions → ↑mucociliary clearance. Also stimulates cough reflex.
Mucolytics (e.g., carbocisteine) ^[2]	Oral medication that breaks disulphide bonds in mucus glycoproteins.	↓Mucus viscosity → easier to expectorate.

Why is airway clearance so important? Every millilitre of stagnant mucus you help the patient clear is a millilitre of bacterial culture medium removed. This directly reduces bacterial load → ↓inflammation → ↓further wall damage. Patients should perform airway clearance daily (not just during exacerbations).

Exam Pearl — DNase in Bronchiectasis

Nebulised recombinant human DNase (dornase alfa, Pulmozyme) is used in CF bronchiectasis to break down extracellular DNA in thick sputum (from neutrophil NETs). However, it is CONTRAINDICATED in non-CF bronchiectasis — a randomised trial (O'Donnell 1998) showed that DNase worsened lung function and increased exacerbation frequency in non-CF bronchiectasis. The sputum composition is different: CF sputum is DNA-rich; non-CF bronchiectasis sputum has different rheological properties.

"Tailored therapies to improve overall physical and psychological conditions" ^[2].

Component	Details	Rationale
Physical training	Breathing training (pursed lip breathing, diaphragmatic breathing), inspiratory muscle training, limb aerobic and resistive training, neuromuscular electrical stimulation ^[2]	↑Respiratory muscle strength → more effective cough → better clearance. Aerobic training ↑mitochondrial density in skeletal muscle → prevent deconditioning. Pursed lip breathing creates auto-PEEP → splints open airways → ↓dynamic hyperinflation.
Energy conservation techniques	Work ergometry and workflow ^[2]	Patients with chronic lung disease waste energy on inefficient breathing patterns. Teaching energy conservation ↑functional capacity for ADLs.
Nutrition	Maintain muscle mass ^[2]	Chronic inflammation → catabolic state → sarcopenia → ↓respiratory muscle strength → worsened clearance. Adequate protein and calorie intake counteracts this.
Psychological counselling	Coping strategies, anxiety/depression management	Chronic productive cough, haemoptysis, and recurrent hospitalisations → significant psychological burden.
Education	Inhaler technique, LTOT use, smoking cessation ^[2]	Empowers patient self-management.

Vaccine	Rationale
Annual influenza vaccine	Influenza → epithelial damage + ↓mucociliary clearance → secondary bacterial infection → triggers exacerbation. Vaccination ↓this risk.
Pneumococcal vaccine (PCV15/20 or PPSV23)	S. pneumoniae is a common exacerbation pathogen. Vaccination ↓invasive pneumococcal disease and pneumonia.
COVID-19 vaccine	Respiratory viral infections are the most common trigger of exacerbations (~40%) ^[12].

Smoking cessation ^[2] is critical even though bronchiectasis classically occurs in non-smokers. Any smoking accelerates mucociliary impairment (ciliotoxic effect of cigarette smoke), promotes further airway inflammation, and increases the risk of COPD-bronchiectasis overlap.

C. Management of Acute Exacerbations

An acute exacerbation is defined as deterioration in ≥3 of the following symptoms for ≥48 hours requiring alteration in treatment: cough, sputum volume and/or consistency, purulence, SOB/exercise tolerance, fatigue/malaise, haemoptysis ^[12].

Aspect	Details
First step	Sputum C/ST before starting antibiotics ^[2] — to guide targeted therapy once results are available.
Empirical therapy	IV piperacillin-tazobactam (Tazocin) is the first-line empirical antibiotic ^[2]^[12].
Duration	10–14 days ^[2]^[12].
Why Tazocin?	Piperacillin is an anti-pseudomonal penicillin (broad-spectrum, covers Pseudomonas aeruginosa — the most important pathogen in severe bronchiectasis). Tazobactam is a β-lactamase inhibitor that prevents enzymatic degradation of piperacillin by bacterial β-lactamases. Together: excellent coverage of the typical bronchiectasis flora including Pseudomonas, H. influenzae, and S. aureus.

Alternative antibiotics for exacerbations ^[12]:

Drug Class	Example	Notes
3rd/4th generation cephalosporins	Ceftazidime, cefepime	Anti-pseudomonal cephalosporins. Ceftazidime is particularly active against Pseudomonas.
Carbapenems	Meropenem, imipenem	Ultra-broad spectrum; reserved for severe/resistant cases. Imipenem requires co-administration with cilastatin (renal dehydropeptidase inhibitor that prevents renal tubular degradation of imipenem).
Aminoglycosides	Amikacin, gentamicin	Usually NOT as monotherapy due to ↑resistance rate ^[12]. Used as adjunctive dual therapy for severe Pseudomonas exacerbations. Nephrotoxic and ototoxic — monitor levels.
Fluoroquinolones	Levofloxacin, ciprofloxacin	Oral option with anti-pseudomonal activity (ciprofloxacin). Useful for outpatient management of mild-moderate exacerbations in Pseudomonas-colonised patients. Caution: tendon rupture, QT prolongation, C. difficile.

HA (Hong Kong) Guideline — Pneumonia in Bronchiectasis Patients

"For patients with chronic lung disease such as bronchiectasis, use antipseudomonal antibiotics (e.g., IV piperacillin-tazobactam (Tazocin) or cefepime) ± macrolide or doxycycline" ^[14]. This is distinct from standard CAP empirical therapy (amoxicillin-clavulanate) — bronchiectasis patients harbour different flora including Pseudomonas.

Dual therapy for Pseudomonas-related exacerbations (e.g., anti-pseudomonal β-lactam + aminoglycoside) — rationale: ↑synergistic killing, ↓emergence of resistance.
Extended infusions of β-lactams — β-lactams are time-dependent killers (efficacy depends on the duration that drug concentration remains above the MIC, not the peak concentration). Extending the infusion time (e.g., 3–4 hour infusion instead of 30 min bolus) maximises the time above MIC → better bacterial killing.

Note: these strategies are NOT proven in controlled trials and remain controversial ^[12]. They are considered in critically ill or deteriorating patients.

D. Prevention of Recurrent Exacerbations

For patients with ≥3 exacerbations per year ^[2], additional strategies are warranted:

Aspect	Details
Drug	Azithromycin (most commonly used) ^[2]^[12]
Dose	Typically 250 mg three times per week or 500 mg three times per week
Mechanism	Azithromycin has dual actions: (1) Direct antibacterial effect (inhibits bacterial 50S ribosomal subunit → ↓protein synthesis), and (2) Immunomodulatory/anti-inflammatory effect — ↓neutrophil chemotaxis, ↓pro-inflammatory cytokine production (IL-8, TNF-α), ↓mucus hypersecretion. The immunomodulatory effect is the primary rationale for long-term use.
Evidence	Multiple RCTs (EMBRACE, BAT, BLESS trials) show ↓exacerbation frequency by ~50%, improved quality of life.
Duration	Usually at least 6–12 months; reassess benefit.
Contraindications / Cautions	Must exclude active NTM infection before starting — macrolide monotherapy drives macrolide-resistant NTM, which makes subsequent NTM treatment far more difficult. Also: ↑QTc prolongation risk, hepatotoxicity, hearing impairment (audiometry monitoring recommended), GI side effects.

Critical — Screen for NTM Before Macrolide Prophylaxis

Before starting long-term azithromycin, obtain sputum AFB cultures ×3 to exclude NTM infection. Macrolide monotherapy in unrecognised NTM infection selects for macrolide-resistant strains → renders the patient's NTM essentially untreatable with standard regimens (macrolide is the backbone of NTM therapy ^[12]).

Aspect	Details
Indication	Patients with chronic Pseudomonas colonisation and frequent exacerbations despite oral macrolide ^[2]^[12]
Drugs	Inhaled colistin (polymyxin E), inhaled tobramycin, inhaled gentamicin
Mechanism	Delivers high-concentration antibiotic directly to the airway surface → high local drug levels at the site of infection with minimal systemic absorption → ↓systemic side effects while maximising anti-pseudomonal killing.
Rationale	Pseudomonas forms biofilms in dilated airways. High local antibiotic concentrations are needed to penetrate the biofilm matrix. Systemic antibiotics often fail to achieve adequate airway concentrations.

When P. aeruginosa is first isolated from sputum, an eradication attempt should be made:

Typically: oral ciprofloxacin (750 mg BD for 2 weeks) ± inhaled colistin or tobramycin for 3 months.
Goal: achieve culture-negative sputum before chronic colonisation is established.
Once chronically colonised, eradication is rarely achievable → shift to suppressive therapy.

Therapy	Indication	Mechanism	Contraindications/Notes
Bronchodilators (β₂-agonists, e.g., salbutamol) ^[12]	Patients with obstructive pattern on lung function tests ^[12]	Relax bronchial smooth muscle → ↑airway calibre → ↓air trapping, ↑mucus clearance. Also useful as pre-treatment before nebulised hypertonic saline (which can trigger bronchospasm).	Only for documented reversible component; not routine for all.
Inhaled corticosteroids (ICS)	NOT recommended as routine; limited to those with asthma/COPD overlap ^[12]	↓Eosinophilic airway inflammation (relevant in asthma overlap); no evidence of benefit in non-asthmatic bronchiectasis.	Chronic ICS in non-asthmatic bronchiectasis → ↑risk of local immunosuppression → may ↑bacterial/NTM infection.
Long-term oxygen therapy (LTOT)	Chronic respiratory failure, as per COPD indications ^[12]: PaO₂ ≤ 7.3 kPa (55 mmHg) or ≤ 8 kPa (60 mmHg) with cor pulmonale/polycythaemia; ≥ 15 hours/day	Corrects chronic hypoxaemia → ↓hypoxic pulmonary vasoconstriction → ↓pulmonary hypertension → ↓RV afterload → ↓cor pulmonale progression. Also ↑exercise tolerance and ↓mortality.	Contraindicated in active smokers (fire risk).
Tranexamic acid	Moderate to severe haemoptysis ^[12]	Antifibrinolytic — inhibits plasminogen activation → stabilises clots at bleeding sites in bronchial arteries.	Risks: tenacious clots can obstruct airways; risk of thromboembolism ^[12]. Use with caution and monitor closely.

Haemoptysis in bronchiectasis is typically associated with acute infective episodes due to injury to hypertrophied bronchial arterioles ^[12].

Severity	Management
Mild (blood-streaked sputum)	Treat the underlying infection with appropriate antibiotics. Reassure patient.
Moderate (persistent, > few tablespoons)	Bed rest + hospitalisation. Empirical antibiotics. Tranexamic acid ^[12].
Severe/Massive (life-threatening)	Secure airway (most important!) → Lie on side of bleeding lung → IV access + O₂ → Urgent bloods (CBC, clotting, T&S, ABG) → CXR → Early bronchoscopy to localise site → Bronchial artery angiogram + embolisation (BAE) ^[5]^[12]. If BAE fails → surgical resection ^[12].

Massive Haemoptysis — Management Priority

The patient dies from asphyxia (drowning in blood), NOT from haemodynamic compromise ^[5]. The AIRWAY is the priority. Lie patient on the bleeding side (protects the good lung). Avoid sedation and cough suppressants ^[5] — the patient needs to cough out blood, not aspirate it. BAE is the first-line definitive intervention for uncontrollable haemoptysis ^[5]^[12].

Procedure	Indication	Details
Lobectomy / Segmentectomy	Localised bronchiectasis confined to a single lobe or segment with recurrent exacerbations, recurrent haemoptysis, or resistant NTM despite maximal medical therapy ^[2]^[12]	Removes the diseased segment entirely → eliminates the reservoir of infection. Only feasible if disease is localised AND the patient has adequate respiratory reserve post-resection.
Bronchial artery embolisation (BAE)	Life-threatening haemoptysis ^[2]^[5]^[12]	Interventional radiology procedure: catheter inserted via femoral artery → selective catheterisation of hypertrophied bronchial arteries → embolisation with particles, coils, or PVA → occludes the bleeding vessel. Recurrence rate ~10–30% (collateral vessels may reopen).
Lung transplantation	End-stage bilateral bronchiectasis in young, fit patients refractory to maximal medical therapy ^[2]^[12]	Must be bilateral lung transplantation ^[12] — rationale: post-transplant immunosuppression means the transplanted lung may be cross-infected by the native diseased lung ^[12]. If you leave one infected lung in situ, it will seed infection into the new graft.

Why Bilateral Transplant for Bronchiectasis?

"Bilateral lung transplantation if bilateral infective pathology, e.g., cystic fibrosis, bronchiectasis" ^[12]. The reason is elegant and logical: after transplantation, the patient receives immunosuppression (to prevent graft rejection). If one diseased, chronically infected lung is left behind, the immunosuppressed patient cannot fight the ongoing infection, and bacteria/NTM from the native lung will cross-contaminate the new graft. Therefore, BOTH lungs must be replaced.

Management Goal	Intervention	Key Drug / Technique
Treat underlying cause	Disease-specific	ABPA: steroids + itraconazole; CVID: IVIG; GERD: PPI
Airway clearance	Physical techniques + nebulisation	Postural drainage, chest percussion, ACBT, PEP devices, nebulised hypertonic saline
Pulmonary rehab	Multidisciplinary	Physical training, nutrition, education, psychological support
Vaccination	Preventive	Influenza (annual), pneumococcal, COVID-19
Acute exacerbation	Antibiotics	IV Tazocin × 10–14 days (empirical); alternatives: ceftazidime, carbapenems, FQ
Prevent recurrence	Long-term antibiotics	Azithromycin (immunomodulatory); inhaled anti-pseudomonal Abx
Haemoptysis	Stepwise	Antibiotics → tranexamic acid → BAE → surgery
Surgery	Selected cases	Lobectomy (localised), BAE (haemoptysis), bilateral lung transplant (end-stage)
LTOT	Respiratory failure	≥ 15 h/day if chronic hypoxaemia meets criteria

High Yield Summary

Management philosophy: Break the vicious cycle at every node — treat cause, clear mucus, treat infection, reduce inflammation, prevent complications.

Airway clearance is the cornerstone — postural drainage, chest percussion, ACBT, PEP devices, nebulised hypertonic saline. Performed DAILY, not just during exacerbations.

Acute exacerbation: Sputum C/ST → empirical IV Tazocin × 10–14 days ^[2]^[12]. Use antipseudomonal antibiotics (NOT standard Augmentin).

Prevent recurrence (≥3/year): Long-term azithromycin for dual antibacterial + immunomodulatory effect ^[2]. Must exclude NTM before starting.

Pseudomonas colonisation = marker of severity. Attempt eradication on first isolation; chronic colonisation → inhaled anti-pseudomonal antibiotics.

Massive haemoptysis: Secure airway → lie on bleeding side → BAE ^[5]^[12]. Patient dies from asphyxia, not blood loss.

Surgery: Lobectomy only if localised. Lung transplantation must be bilateral due to cross-infection risk ^[12].

DNase (Pulmozyme) is CONTRAINDICATED in non-CF bronchiectasis — worsens outcomes.

ICS NOT routine — only if asthma/COPD overlap ^[12].

Active Recall - Bronchiectasis Management

References

^[1] Lecture slides: GC 052. Fever and purulent sputum.pdf (slide 43 — Bronchiectasis: investigations) ^[2] Senior notes: Maksim Medicine Notes.pdf (p.304 — Bronchiectasis management) ^[4] Senior notes: Jerry's immunodeficiencies.pdf (p.1, p.3 — CVID, CGD management) ^[5] Senior notes: Ryan Ho Fundamentals.pdf (p.226 — Haemoptysis approach and management) ^[12] Senior notes: Ryan Ho Respiratory.pdf (p.93, 132–133 — NTM treatment, acute exacerbation, haemoptysis, surgery, adjuncts, lung transplantation) ^[14] Senior notes: Adrian Lui Pediatrics Notes.pdf (p.166 — HA empirical antibiotic guidelines for pneumonia in bronchiectasis)

Complications of Bronchiectasis

Bronchiectasis is not merely a "lung disease with a cough." The vicious cycle of infection, inflammation, and structural destruction has consequences that radiate outward from the airways to involve the pulmonary vasculature, the right heart, distant organs, and the patient's overall systemic health. Understanding these complications requires tracing each one back to the underlying pathophysiology.

The complications can be organised into:

Infective complications — direct consequences of chronic bacterial colonisation and acute exacerbations.
Haemoptysis — from hypertrophied bronchial arteries.
Respiratory complications — progressive airflow limitation leading to respiratory failure.
Cardiovascular complications — pulmonary hypertension and cor pulmonale.
Extrapulmonary / systemic complications — distant organ involvement.
Antimicrobial resistance — an iatrogenic but inevitable consequence of repeated antibiotic courses.

Senior Notes — Complications Summary

Maksim Medicine Notes ^[2] concisely lists the three key complications:

Recurrent infections → Repeated antibiotics → Antimicrobial resistance
Pulmonary hypertension → Cor pulmonale
Respiratory failure

These form the backbone, but additional complications are elaborated below.

1. Recurrent Infective Exacerbations and Their Sequelae

Bronchiectasis is a common underlying structural cause of recurrent pneumonia ^[14]^[15].
Why? Dilated, mucus-filled airways are permanent reservoirs of bacteria. Any additional insult (viral URTI triggers ~40% of exacerbations ^[12], air pollution, aspiration) destabilises the equilibrium → acute ↑bacterial load → pneumonia in the already-damaged lung segments.
Recurrent pneumonia is defined as ≥2 episodes in a year or ≥3 episodes at any time with radiographic clearing between episodes ^[14].
Each bout of pneumonia causes further parenchymal and bronchial wall destruction → accelerates the vicious cycle → more severe bronchiectasis → more recurrent infections. This is a self-amplifying spiral.

Mechanism: Severe infection in a cystic bronchiectatic segment with poor drainage → contained collection of pus → parenchymal necrosis → lung abscess.
Often polymicrobial (aerobes + anaerobes, particularly Fusobacterium, Peptostreptococcus, Bacteroides from aspiration of oropharyngeal flora).
Clinical clue: Fever spikes with foul-smelling sputum (anaerobes produce volatile sulphur compounds); CXR/CT shows a thick-walled cavity with an air-fluid level within the affected lobe.

Mechanism: Infection in a subpleural bronchiectatic segment breaches the visceral pleura → bacteria enter the pleural space → initially a parapneumonic effusion (reactive, sterile) → progresses to empyema (pus in the pleural space) ^[14].
A complicated parapneumonic effusion / empyema requires chest tube drainage ± surgical decortication. Without drainage, the fibrinopurulent material organises into a thick peel ("fibrothorax") that restricts lung expansion.

Severe exacerbations can lead to bacteraemia → septicaemia with multi-organ failure ^[14].
Brain abscess is a classic distant complication of bronchiectasis. Why? Bacteria from the chronically infected lung enter the systemic venous circulation. Normally, the pulmonary capillary bed acts as a filter — but in bronchiectasis, intrapulmonary shunts (from destroyed capillary beds and bronchopulmonary anastomoses) allow bacteria to bypass the lung filter and enter the systemic arterial circulation → haematogenous seeding to the brain (especially via the middle cerebral artery territory at the grey-white junction) ^[16].
This is the same mechanism as in other chronic suppurative lung diseases (empyema, lung abscess) and congenital heart disease with right-to-left shunts.

Why the grey-white junction? This is where the terminal branches of cortical arteries meet the medullary branches — a watershed zone with relatively sluggish flow, making it vulnerable to septic emboli lodging and establishing infection.

Haemoptysis is one of the most feared complications and a leading cause of emergency presentation in bronchiectasis.
Mechanism (revision): Chronic airway inflammation → neovascularisation and hypertrophy of bronchial arteries (systemic pressure, ~120 mmHg). These tortuous, thin-walled vessels are friable → rupture during infective exacerbations or with mechanical stress from coughing.
Haemoptysis is typically associated with acute infective episodes ^[12] — infection increases local inflammation, vessel wall fragility, and coughing force.
Massive haemoptysis ( > 100–200 mL/day) is life-threatening — death is from asphyxia (flooding of the alveoli with blood → impaired gas exchange → hypoxic cardiac arrest), NOT from exsanguination ^[5].
Management: antibiotics for the underlying infection → tranexamic acid → bronchial artery embolisation (BAE) → surgical resection as last resort ^[2]^[12].

Mechanism: Progressive bronchial and parenchymal destruction over years → cumulative loss of functional lung tissue + worsening airflow obstruction → eventually the remaining lung cannot maintain adequate gas exchange.
Two patterns:

Type	Pathophysiology	ABG	Stage
Type I respiratory failure (hypoxaemic)	V/Q mismatch — mucus-plugged and destroyed segments are poorly ventilated but still perfused → venous admixture → hypoxaemia. Initially compensated by hyperventilation → normal or ↓PaCO₂.	↓PaO₂, normal/↓PaCO₂	Earlier / moderate disease
Type II respiratory failure (hypercapnic)	Severe disease → respiratory muscle fatigue + extensive airflow obstruction + ↑dead space → the respiratory pump can no longer maintain alveolar ventilation → CO₂ retention.	↓PaO₂, ↑PaCO₂	Late / end-stage disease

Clinical signs: Central cyanosis (Type I → severe Type II), CO₂ retention flap (asterixis), bounding pulse, drowsiness (CO₂ narcosis), use of accessory muscles, tachypnoea.
Management: LTOT (long-term oxygen therapy) ≥15 h/day for chronic hypoxaemia meeting criteria; non-invasive ventilation (NIV) for chronic hypercapnic failure ^[12].

This is a critical complication pathway to understand from first principles:

Chronic hypoxaemia
    → Hypoxic pulmonary vasoconstriction (HPV)
        → ↑ Pulmonary vascular resistance (PVR)
            → Pulmonary hypertension (pHTN)
                → ↑ RV afterload
                    → RV hypertrophy (compensatory)
                        → Eventually RV dilatation and failure
                            = COR PULMONALE

Hypoxic pulmonary vasoconstriction (HPV) is a physiological mechanism: pulmonary arterioles constrict in response to alveolar hypoxia to divert blood away from poorly ventilated areas towards better-ventilated areas (optimises V/Q matching). However, when hypoxia is chronic and widespread (as in severe bronchiectasis), HPV becomes pathological — it raises PVR globally.
Over time, chronic ↑PVR leads to pulmonary vascular remodelling (intimal hyperplasia, medial hypertrophy of pulmonary arterioles) → irreversible pulmonary hypertension.
The right ventricle, which is a thin-walled, compliant pump designed for a low-pressure circuit, struggles against the ↑afterload → initially hypertrophies (compensated) → eventually dilates and fails (decompensated) → cor pulmonale.

Clinical signs of cor pulmonale ^[12]:

↑JVP (back-pressure from failing RV → ↑central venous pressure)
Peripheral oedema (↑systemic venous pressure → ↑capillary hydrostatic pressure → fluid transudation into interstitium)
Hepatomegaly / hepatic congestion (hepatic veins drain into the IVC → back-pressure → hepatic congestion → tender, pulsatile hepatomegaly)
Parasternal heave (RV hypertrophy lifts the sternum during systole)
Loud P2 (↑pulmonary artery pressure → forceful closure of pulmonary valve)
Tricuspid regurgitation (RV dilatation → stretching of tricuspid annulus → incompetent valve → pansystolic murmur at left lower sternal edge, ↑on inspiration)

This is classified as Group 3 pulmonary hypertension (pHTN due to lung diseases and/or hypoxia) in the clinical classification of pulmonary hypertension ^[17].

"Recurrent infections → Repeated antibiotics → Antimicrobial resistance" ^[2].

This is an inevitable consequence of the disease and its treatment. Patients with bronchiectasis receive multiple courses of antibiotics (10–14 days per exacerbation, often 3+ exacerbations per year, plus long-term prophylactic macrolides or inhaled antibiotics).
Mechanism of resistance emergence:
- Subtherapeutic antibiotic concentrations in biofilms within dilated airways → selective pressure favouring resistant mutants.
- Pseudomonas aeruginosa is particularly adept at developing resistance: it has intrinsic efflux pumps, can acquire resistance genes via horizontal transfer, and produces biofilms that shield bacteria from antibiotics.
- Long-term macrolide use → macrolide-resistant organisms (including NTM — hence the critical need to exclude NTM before starting azithromycin prophylaxis).
Clinical consequence: Over time, treatment options narrow. Multi-drug resistant (MDR) Pseudomonas or Stenotrophomonas maltophilia may emerge, requiring last-resort antibiotics (colistin, ceftazidime-avibactam) or combination regimens.

6. Extrapulmonary and Systemic Complications

Mechanism: Chronic suppurative inflammation (decades of bronchiectasis) → sustained ↑production of serum amyloid A (SAA) protein by the liver (an acute-phase reactant) → misfolded SAA deposits as AA amyloid fibrils in tissues (kidneys, liver, spleen, GI tract).
Renal involvement is the most common clinical manifestation: nephrotic syndrome (heavy proteinuria, hypoalbuminaemia, oedema) progressing to renal failure.
This complication has become rare with modern management (better infection control, effective antibiotics) but historically was a major cause of death in bronchiectasis.

Chronic airway infection → sustained release of pro-inflammatory cytokines (TNF-α, IL-1, IL-6) into the systemic circulation → chronic systemic inflammatory state.
Consequences:
- Cachexia / weight loss — TNF-α (historically called "cachectin") drives muscle wasting and anorexia.
- Anaemia of chronic disease — IL-6 stimulates hepcidin production by the liver → hepcidin blocks ferroportin on enterocytes and macrophages → iron sequestration → ↓iron availability for erythropoiesis → normochromic normocytic anaemia.
- Fatigue and reduced quality of life.

As discussed above — haematogenous spread through intrapulmonary shunts ^[16].
Classically presents with headache (most common symptom), fever, focal neurological deficits, and seizures.
Multiple abscesses in the MCA territory at the grey-white junction.

Chronic productive cough (socially embarrassing), recurrent hospitalisations, haemoptysis (frightening), exercise limitation, and the prospect of progressive decline → high rates of anxiety and depression.
Pulmonary rehabilitation programmes incorporate psychological counselling for this reason ^[2].

Some complications are specific to the underlying cause of bronchiectasis rather than bronchiectasis itself:

Aetiology	Aetiology-Specific Complications
Cystic fibrosis	Pancreatic insufficiency → malabsorption, diabetes (CF-related diabetes), distal intestinal obstruction syndrome (DIOS), infertility, liver cirrhosis
CVID	Autoimmune cytopenias (ITP, AIHA), granulomatous disease, ↑risk of GI and lymphoid malignancies ^[4]
Primary ciliary dyskinesia	Chronic sinusitis, otitis media → conductive hearing loss, male infertility
Post-TB	Apical fibrosis, chronic pulmonary aspergillosis (aspergilloma forming in residual TB cavities), risk of lung cancer ("scar carcinoma") ^[12]

Category	Complication	Mechanism
Infective	Recurrent pneumonia, lung abscess, empyema, septicaemia, brain abscess	Chronic bacterial reservoir in dilated airways; haematogenous spread bypassing pulmonary filter
Haemoptysis	Mild to massive	Hypertrophied bronchial arteries (systemic pressure) rupture during infection/coughing
Respiratory	Type I → Type II respiratory failure	Progressive loss of functional lung + airflow obstruction → V/Q mismatch → ventilatory failure
Cardiovascular	Pulmonary hypertension → cor pulmonale	Chronic hypoxia → HPV → ↑PVR → RV pressure overload → RV failure
Iatrogenic	Antimicrobial resistance	Repeated antibiotic exposure → selection of resistant organisms (especially Pseudomonas)
Systemic	AA amyloidosis, cachexia, anaemia of chronic disease, depression	Chronic systemic inflammation (TNF-α, IL-6, SAA)

High Yield Summary

Core complications to remember (exam framework):

Recurrent infections → Repeated antibiotics → Antimicrobial resistance ^[2] — the self-perpetuating treatment dilemma.
Pulmonary hypertension → Cor pulmonale ^[2] — chronic hypoxia → HPV → ↑PVR → RV failure. Signs: ↑JVP, peripheral oedema, parasternal heave, loud P2.
Respiratory failure ^[2] — progressive Type I (hypoxaemic) → Type II (hypercapnic) in end-stage disease.
Massive haemoptysis — hypertrophied systemic-pressure bronchial arteries; death from asphyxia, not exsanguination. Treat with BAE.
Brain abscess — haematogenous spread via intrapulmonary shunts; MCA territory, grey-white junction.
AA amyloidosis — rare now but historically important; chronic SAA overproduction → renal amyloid deposition.
Empyema and lung abscess — direct extension of infection.

Key clinical signs of cor pulmonale: ↑JVP, peripheral oedema, hepatomegaly, parasternal heave, loud P2, TR murmur.

Active Recall - Complications of Bronchiectasis

References

^[2] Senior notes: Maksim Medicine Notes.pdf (p.304 — Bronchiectasis complications) ^[4] Senior notes: Jerry's immunodeficiencies.pdf (p.1 — CVID complications) ^[5] Senior notes: Ryan Ho Fundamentals.pdf (p.226 — Massive haemoptysis approach) ^[12] Senior notes: Ryan Ho Respiratory.pdf (p.76, 128–133 — Post-TB bronchiectasis, bronchiectasis pathogenesis, clinical features, acute exacerbation, haemoptysis management) ^[14] Senior notes: Adrian Lui Pediatrics Notes.pdf (p.167 — Pneumonia complications and recurrent pneumonia) ^[15] Lecture slides: Investigations of Imm Disorders 2025.pdf (p.13 — Case of immunodeficiency with traction bronchiectasis) ^[16] Senior notes: Ryan Ho Neurology.pdf (p.150 — Brain abscess aetiology: bronchiectasis as cause of haematogenous spread) ^[17] Senior notes: Block A - Three Cases of Dyspnea.pdf (p.3 — Pulmonary hypertension classification, Group 2/3)